Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

This Phase 3 clinical trial investigates the efficacy and safety of ritlecitinib at 50 mg and 100 mg doses for treating severe alopecia areata in patients aged 12 and older with at least 50% scalp hair loss. The study involves 550 participants and uses an innovative design with external and synthetic placebo control groups, eliminating the need for new patients to be randomized to a placebo. The primary outcome is measured by the Severity of Alopecia Tool (SALT) score, with the main goal being to compare the effectiveness of the 100 mg dose against the 50 mg dose and placebo over 48 weeks. The trial aims to address the unmet need for more effective AA treatments, as current therapies often fall short in efficacy.